Business Context and Reporting Period
This Form 8-K filing by Gossamer Bio, Inc. (GOSS) reports on the results of the Company's annual meeting of stockholders held on June 9, 2022. The filing details the voting outcomes for director elections, auditor ratification, and executive compensation.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a report on corporate governance voting results.
Material Changes
No material financial changes are reported in this document. The filing confirms the successful re-election of the Class I directors and the ratification of the independent auditor.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies. It solely presents the vote tallies for the three matters submitted to security holders.
Important Facts for Investors
- Director Election: Three Class I directors were re-elected for a three-year term expiring in 2025: Kristina Burow, Thomas Daniel, M.D., and Sandra Milligan, M.D., J.D.
- Auditor Ratification: Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Executive Compensation: The advisory vote on the compensation of named executive officers was approved by stockholders.
- Voting Participation: Significant broker non-votes were recorded for the director election and executive compensation proposals (12,761,120 votes), while the auditor ratification had no broker non-votes.